US2005074410A1PendingUtilityA1
Methods for diagnosis of allergic bronchopulmonary aspergillosis
Priority: Dec 20, 1996Filed: Jul 2, 2003Published: Apr 7, 2005
Est. expiryDec 20, 2016(expired)· nominal 20-yr term from priority
G01N 33/6854
34
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A method for the diagnosis of ABPA in a human individual, comprising determining if the individual carries antibodies reactive with one or more ABPA-related recombinant allergens.
Claims
exact text as granted — not AI-modified1 - 13 . (canceled)
14 . A method for the diagnosis of ABPA in a human individual, comprising determining if the individual carries antibodies reactive with one or more ABPA-related recombinant allergens which discriminate with 100% specificity between ABPA and allergic sensitization to A. fumigatus.
15 . The method according to claim 14 , wherein the allergen is derived from A. fumigatus.
16 . The method according to claim 15 , wherein the allergen corresponds to a non-secreted protein from A. fumigatus.
17 . The method according to claim 14 , wherein an in vitro immunoassay is carried out on a fluid sample from the individual for the determination of the level of antibodies directed towards said recombinate allergens.
18 . The method according to claim 17 , wherein antibodies of the IgE class or IgE class, or subclasses thereof, are determined.
19 . The method according to claim 17 , wherein antibodies of the IgE class are determined.
20 . The method according to claim 14 , wherein an in vivo test is carried out in the individual.
21 . The method according to claim 20 , wherein the test is a skin test involving placing said one or more ABPA-related recombinant allergens in the skin of the patient.
22 . The method according to claim 20 , wherein antibodies of the IgE class or IgE class, or subclasses thereof, are determined.
23 . The method according to claim 20 , wherein antibodies of the IgE class are determined.Join the waitlist — get patent alerts
Track US2005074410A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.